Request Copyright Permission

Pulmonary Delivery of Monoclonal Antibody Spray-Dried Dispersions: Local Treatment of Non-Small-Cell Lung Cancer with Bevacizumab

Shepard K, Vodak D, Kuehl PJ, Revelli D, Pluntze A, Adam M, Oddo J, Switala L, Baumann J, Banks M.

Respiratory Drug Delivery 2021. Volume , 2021: 99-108.

Abstract:

Locally administered biologics are of great interest for treatment of lung diseases, but development of shelf-stable, dry-powder formulations for inhalation has remained a challenge. This work describes manufacture of a monoclonal antibody (mAb) as a stable, respirable, biologically active pulmonary formulation using spray drying. This case study was focused on bevacizumab, which is approved for treatment of non-small-cell lung cancer (NSCLC) by intravenous (IV) infusion. A bevacizumab spray-dried dispersion (SDD) was successfully prepared. Using in vivo tests with an orthotopic nude rat model, the inhaled bevacizumab SDD was shown to reduce NSCLC tumor burden at one-tenth the dose used for the injected bevacizumab control formulation.